Kestra Advisory Services LLC bought a new position in shares of agilon health, inc. (NYSE:AGL – Get Rating) in the 3rd quarter, HoldingsChannel.com reports. The fund bought 45,594 shares of the company's stock, valued at approximately $1,068,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. FMR LLC increased its stake in agilon health by 14.9% during the second quarter. FMR LLC now owns 34,862,287 shares of the company's stock worth $761,043,000 after acquiring an additional 4,512,008 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of agilon health by 11.0% in the first quarter. Wellington Management Group LLP now owns 18,578,035 shares of the company's stock valued at $470,953,000 after buying an additional 1,834,890 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of agilon health by 1.4% in the first quarter. Vanguard Group Inc. now owns 13,235,600 shares of the company's stock valued at $335,522,000 after buying an additional 177,239 shares in the last quarter. Capital Research Global Investors grew its stake in shares of agilon health by 18.4% in the first quarter. Capital Research Global Investors now owns 9,867,875 shares of the company's stock valued at $250,151,000 after buying an additional 1,536,506 shares in the last quarter. Finally, Brown Advisory Inc. grew its stake in shares of agilon health by 0.4% in the second quarter. Brown Advisory Inc. now owns 3,513,368 shares of the company's stock valued at $76,697,000 after buying an additional 13,323 shares in the last quarter.

Insiders Place Their Bets

In other agilon health news, insider Benjamin Kornitzer sold 5,398 shares of agilon health stock in a transaction dated Friday, December 16th. The stock was sold at an average price of $16.82, for a total transaction of $90,794.36. Following the completion of the sale, the insider now directly owns 10,426 shares of the company's stock, valued at approximately $175,365.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other agilon health news, insider Benjamin Shaker sold 20,723 shares of agilon health stock in a transaction dated Wednesday, January 18th. The stock was sold at an average price of $19.78, for a total transaction of $409,900.94. Following the completion of the sale, the insider now directly owns 25,625 shares of the company's stock, valued at approximately $506,862.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin Kornitzer sold 5,398 shares of agilon health stock in a transaction dated Friday, December 16th. The stock was sold at an average price of $16.82, for a total value of $90,794.36. Following the sale, the insider now directly owns 10,426 shares of the company's stock, valued at $175,365.32. The disclosure for this sale can be found here. Insiders sold 39,613 shares of company stock valued at $746,114 in the last ninety days. Insiders own 3.30% of the company's stock.

agilon health Trading Down 3.6 %

agilon health (NYSE:AGL – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.02). The business had revenue of $694.86 million for the quarter, compared to analysts' expectations of $651.24 million. agilon health had a negative return on equity of 9.31% and a negative net margin of 4.30%. Sell-side analysts expect that agilon health, inc. will post -0.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on AGL. Stifel Nicolaus began coverage on agilon health in a research note on Thursday, December 8th. They issued a "buy" rating and a $23.00 price objective for the company. Wells Fargo & Company dropped their price objective on agilon health from $28.00 to $22.00 and set an "overweight" rating for the company in a research note on Tuesday, November 15th. SVB Leerink dropped their price objective on agilon health from $33.00 to $30.00 and set an "outperform" rating for the company in a research note on Friday, November 4th. Finally, The Goldman Sachs Group dropped their price objective on agilon health from $38.00 to $34.00 and set a "buy" rating for the company in a research note on Tuesday, November 15th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $28.38.

agilon health Company Profile

(Get Rating)

agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries.

Featured Stories

• Get a free copy of the StockNews.com research report on agilon health (AGL)
• Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
• How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
• Is the Pain Over for Baudax Bio Investors after a 70% Spike?
• Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
• When Will Crane Holdings Take Flight?

Want to see what other hedge funds are holding AGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for agilon health, inc. (NYSE:AGL – Get Rating).

Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.